The market is expected to grow at a 2% rate to 2033, and an Australian company is poised to lead the way.
Rising prostate cancer numbers are driving a need for early detection, according to data and analytics company GlobalData, and one Australian diagnostics company is meeting that demand with next-level positron emission tomography.
Telix Pharmaceuticals says its Illuccix (gallium-68 [68Ga] gozetotide injection kit) enables precise detection of both advanced and localised prostate cancer, targeting prostate-specific membrane antigen (PSMA) positive lesions.
The Australian PET imaging market accounted for around 10% of the Asia-Pacific market last year. Telix Pharmaceuticals’ imaging agent has been getting attention outside the region as well, with approval just granted in Brazil.
“PSMA-targeted PET imaging represents a significant advancement in the detection of prostate cancer, particularly in its early stages or when PSA levels are low. The heightened sensitivity of PSMA PET imaging enables the identification of even small lesions that conventional methods may overlook, thus contributing to earlier detection and more precise staging,” said Nidhi Bharti, medical devices analyst at GlobalData.
“PSMA-PET imaging is becoming a key tool in prostate cancer care. This technology allows clinicians to identify even the smallest lesions, providing crucial information that can directly influence treatment decisions, offering hope for more effective, individualized care, and ultimately improving patient survival rates.”
